Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection

Thomas Geisbert, James E. Strong, Heinz Feldmann

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions.

Original languageEnglish (US)
Pages (from-to)S91-S97
JournalJournal of Infectious Diseases
Volume212
DOIs
StatePublished - Oct 1 2015

Fingerprint

Marburgvirus
Ebolavirus
Virus Diseases
Primates
Ebola Hemorrhagic Fever
Medical Licensure
Western Africa
Euthanasia
Uridine
Zoonoses
Macaca mulatta
Disease Outbreaks
Glycoproteins
Fever
Vaccines
Public Health
Viruses
Mortality
Infection
Therapeutics

Keywords

  • animal model
  • Ebola virus
  • filovirus
  • Marburg virus
  • nonhuman primate
  • treatment
  • vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection. / Geisbert, Thomas; Strong, James E.; Feldmann, Heinz.

In: Journal of Infectious Diseases, Vol. 212, 01.10.2015, p. S91-S97.

Research output: Contribution to journalArticle

@article{389fa552e44241569293d9632e52ed3f,
title = "Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection",
abstract = "The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23{\%} to 90{\%}. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions.",
keywords = "animal model, Ebola virus, filovirus, Marburg virus, nonhuman primate, treatment, vaccine",
author = "Thomas Geisbert and Strong, {James E.} and Heinz Feldmann",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/infdis/jiv284",
language = "English (US)",
volume = "212",
pages = "S91--S97",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection

AU - Geisbert, Thomas

AU - Strong, James E.

AU - Feldmann, Heinz

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions.

AB - The filoviruses, Ebola virus and Marburg virus, are zoonotic pathogens that cause severe hemorrhagic fever in humans and nonhuman primates (NHPs), with case-fatality rates ranging from 23% to 90%. The current outbreak of Ebola virus infection in West Africa, with >26 000 cases, demonstrates the long-underestimated public health danger that filoviruses pose as natural human pathogens. Currently, there are no vaccines or treatments licensed for human use. Licensure of any medical countermeasure may require demonstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infection. Substantial progress has been made over the last decade in characterizing the filovirus NHP models. However, there is considerable debate over a variety of experimental conditions, including differences among filovirus isolates used, routes and doses of exposure, and euthanasia criteria, all of which may contribute to variability of results among different laboratories. As an example of the importance of understanding these differences, recent data with Ebola virus shows that an addition of a single uridine residue in the glycoprotein gene at the editing site attenuates the virus. Here, we draw on decades of experience working with filovirus-infected NHPs to provide a perspective on the importance of various experimental conditions.

KW - animal model

KW - Ebola virus

KW - filovirus

KW - Marburg virus

KW - nonhuman primate

KW - treatment

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84943270748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943270748&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv284

DO - 10.1093/infdis/jiv284

M3 - Article

C2 - 26063223

AN - SCOPUS:84943270748

VL - 212

SP - S91-S97

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -